Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study-MedSci.cn

Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study

Schmid, P; Wysocki, P; Ma, C; Park, YH; Fernandes, R; Lord, S; Baird, RD; Prady, C; Jung, KH; Asselah, J; Huisden, R; Stewart, R; Vukovic, P; Nunes, AT; Nowecki, Z

CANCER RESEARCH, 2023; 83 (5):

科室
- - 订阅+
  - 更多科室
工具
服务